Abstract
Objective The aim of our study was to systematically evaluate the prognostic effects of various circrnas and to explore the prognostic value of circRNAs in breast cancer patients.
Methods A systematical search was conducted on PubMed, Scopus, EMBASE, and the Cochrane Library databases. Eligible studies reporting on the association among circRNAs and prognostic values of breast cancer patients were included. Fixed-effects and random effects models were used to calculate the pooled hazard ratio values of overall survival and disease free survival. In addition, funnel plots were used to qualitatively analyze the publication bias.
Results 28 studies were included in our meta-analysis. The pooled hazard ratio values of overall survival and disease free survival related to different circRNAs expression in breast cancer patients were 1.68 (1.44-1.97), 2.63 (1.95-3.53).We have identified a total of 28 circRNAs including 19 significantly up-regulated expression circRNAs and 9 significantly down-regulated expression circRNAs in BC(breast cancer) patients. Moreover, all of them revealed mechanisms and have the function of promoting or inhibiting the proliferation, metastasis or invasion of breast cancer cells by acting on the corresponding target.
Conclusion Overall, specific circRNAs are significantly associated with the prognosis of BC patients and potentially eligible for the prediction of patients survival. It also provides a potential value for clinical decision-making development and may serve as a promising circRNAs-based target therapy waiting for further elucidation.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the Postgraduate Innovation Special Foundation of Jiangxi Province (YC2020-B043)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
NO
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Financial support: This study was supported by the Postgraduate Innovation Special Foundation of Jiangxi Province (YC2020-B043)
Credit author statement XC.L study concept and design, data collection; ZZ.Z data analyzing and article writing; DW.L Obtained funding and critically revised the manuscript.
All of the authors reviewed the manuscript and approved the final version.
Declaration of Competing Interest The authors declare that there are no conflicts of interest.
Data Availability
literature search was performed in the PubMed, Scopus, EMBASE, and the Cochrane Library databases
